Company Overview
China SXT Pharmaceuticals, Inc. operates as a pharmaceutical entity dedicated to the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) within the Chinese market. The company specializes in offering advanced, fine, and regular TCMP products alongside raw medicinal materials such as SanQiFen and HongQi, positioning itself within the broader healthcare ecosystem. This organization is classified under the Healthcare sector and functions specifically within the Drug Manufacturers - Specialty & Generic industry, a classification that defines its focus on producing specific therapeutic agents rather than broad consumer goods. In terms of operational scale, the company maintains a workforce of 75 employees and reports a total market capitalization of $1.11M with trailing twelve-month revenue of $1.54M. The combination of a sub-$2M market cap and annual revenue indicates that the company occupies a niche position in the pharmaceutical landscape, reflecting a small-cap status with limited resources compared to large-cap peers.
Financial Health
The company reported trailing twelve-month revenue of $1.54M, yet simultaneously recorded a net income of $-8,869,886 and an EBITDA of $-8,335,278, revealing a significant divergence between top-line generation and bottom-line profitability. The substantial gap between revenue and net income highlights a cost structure where operating expenses far exceed gross profits, resulting in a net loss that is disproportionately larger than the operating loss. Free cash flow for the period was $-1,948,357, which suggests that the company is currently burning cash rather than generating liquidity from its core operations, thereby limiting its immediate financial flexibility for expansion without external capital. Profitability metrics further illustrate this distress, with a gross margin of 21.7% indicating that production costs consume a majority of revenue, while an operating margin of -1011.7% and a profit margin of 0.0% demonstrate severe inefficiencies or high overhead relative to sales. On the balance sheet, the firm holds $21.31M in cash against $1.20M in debt, creating a net cash position, though the debt-to-equity ratio stands at 5.95, suggesting a leveraged capital structure relative to equity. Despite the leverage, the current ratio of 4.37 indicates strong short-term liquidity, meaning the company possesses ample current assets to cover its current liabilities without immediate distress. Furthermore, return metrics show a return on equity of -50.3% and a return on assets of -18.3%, which reveal that management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both listed as N/A, which implies that the company is currently unprofitable and lacks the earnings necessary to support a standard price-to-earnings valuation metric. Consequently, the market prices the stock based on alternative metrics, starting with a price-to-book ratio of 0.05, which indicates that the stock is trading at a significant discount to its book value. Additionally, the price-to-sales ratio is 0.72 and the EV/EBITDA is 2.29, suggesting that valuation is being driven by revenue multiples and enterprise value metrics rather than earnings power. Regarding trading range volatility, the 52-week high is $1047.00 while the 52-week low is $1.27, meaning the current market price sits extremely close to the bottom of the established trading range. The beta value of 1.74 indicates that the stock is significantly more volatile than the broader market, moving with much greater amplitude than the general index.
Growth & Income
The company experienced a revenue growth rate of -24.5% year-over-year, while earnings growth is listed as N/A due to the lack of positive net income to measure against. Since the earnings are negative, they are not growing faster than revenue in a traditional sense, but rather the company is contracting in terms of profitability alongside its shrinking revenue base. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as the payout ratio is effectively 0.0% because there are no earnings to distribute. This absence of dividend payments suggests that the company retains any available resources, though currently negative, into operations rather than returning capital to shareholders. The overall growth and income profile is characterized by negative revenue expansion and an inability to generate sustainable income, reflecting a high-risk investment characteristic typical of early-stage or distressed biotechnology firms.